Enovis

The staples are the latest additions to Wilmington, Delaware–based Enovis’ growing foot and ankle portfolio. The portfolio includes the DynaClip family of bone fixation systems.

DynaClip Delta and DynaClip Quattro staples come pre-loaded on disposable inserters. The inserters facilitate quick deployment and accurate leg positioning, according to Enovis.

Additionally, Enovis designed the DynaClip Delta staples to enable faster and easier first metatarsophalangeal (MTP) fusion procedures. The company says the staples accomplish this without compromising on durability and performance.

Both DynaClip Delta and DynaClip Quattro use nitinol materials technology that provides sustained dynamic compression across fusion sites, according to Enovis. Unlike traditional nitinol sta…

As with other DynaNail systems, DynaNail Helix uses proprietary, nitinol-based materials technology. The NiTiNOL tech provides sustained dynamic compression properties for subtalar fusion.

At the same time, Enovis sought to give it an anatomically friendly design and simple, screw-like insertion. As a result, the Helix’s threads also allow for easy insertion like a screw while also providing a nail’s dynamic compressive power and stability.

“It provides sustained compression across the fusion site, which traditional screws cannot do,” said Dr. Christopher Hirose, a foot and ankle orthopedic surgeon based in Boise, Idaho.

Hirose added in the Enov…

Enovis (NYSE:ENOV) shares took a hit today on third-quarter results that came in ahead of the consensus forecast.

Shares of ENOV dipped 3.4% at $47.89 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose by 1%.

The Wilmington, Delaware-based company posted losses of $66.5 million for the quarter. That amounts to $1.22 per share on sales of $383.8 million for the three months ended Sept. 30, 2022.

Enovis, the parent company of DJO, recorded a big bottom-line slide into the red on sales growth of 6.6%. The company’s reconstructive segment drove growth with a 15% year-over-year improvement. Ongoing cost inflation provided a negative impact, the company said.

Adjusted to exclude one-time items, earnings per share totaled 59¢. That registered 9¢ ahead of Wall Street. Sales topped analyst expectations, too, as they projected $381.2 million. Read more

The company held a ribbon-cutting ceremony for the facility’s opening on Sept. 27. President of Enovis Surgical, Louis Vogt, and VP of Operations, Shayne Myhand, attended the event. The 40,000-square-foot ISO 9001-certified center complements Enovis’ existing 75,000-square-foot manufacturing facility.

Wilmington, Delaware-based Enovis said the new facility allos it to employ an additional 100 team members. It expects the plant to support increased demand for its reconstructive hip, knee and shoulder implants.

Enovis said new roles at the facility center around distribution support, metal finishing, CNC machining and clean room operations. The company currently employs more than 5,000 people across the world. Earlier this year, the company launched the ARVIS FDA-cleared augmented reality surgical guidance system. Read more

Enovis (NYSE: ENOV) today reported Q2 results that beat The Street on earnings but missed on revenue, with the ortho device company joining the host of medtech companies scaling back earnings projections for the year amid macroeconomic headwinds.

Wilmington, Delaware–based Enovis — the parent company of DJO — earned $121 million, or $2.21 per diluted share, off $395 million in sales for the three months ended July 1, 2022, more than doubling its earnings and growing the top line 11% compared with Q2 2021.

Adjusted to exclude one-time items, Enovis saw earnings per share of 59¢, 9¢ ahead of The Street, where analysts expected sales of $400.97 million.

“We again achieved faster growth than our markets this quarter in both of our business segments,” Enovis CEO Matt Trerotola said ina. news release. “We are executing our strategic priorities, investing in innovation and acquisitions to support our goal to achieve a sustainable high-single-digit organic growt…

Wilmington, Delaware-based Enovis — the parent company of DJO Global — earlier this month completed the acquisition of Insight Medical and its Arvis FDA-cleared augmented reality platform for hip and knee replacement surgery.

According to a news release, Arvis is the only proprietary, real-time, hands-free augmented reality (AR) technology precisely engineered for orthopedic surgeons to visualize precision guidance when performing hip and knee surgery with the support of AR.

The self-contained, wearable surgical guidance device can be worn on a headband or with helmets already worn during surgery. It was designed to ensure surgeons can focus on their patient, rather than a screen across the roo…